BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 30484260)

  • 1. Introduction of the targeted alpha therapy (with Radium-223) into clinical practice in Japan: learnings and implementation.
    Hosono M; Ikebuchi H; Nakamura Y; Yanagida S; Kinuya S
    Ann Nucl Med; 2019 Mar; 33(3):211-221. PubMed ID: 30484260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nursing management of patients with castration-resistant prostate cancer undergoing radium-223 dichloride treatment.
    Delacruz A; Arauz G; Curley T; Lindo A; Jensen T
    Clin J Oncol Nurs; 2015 Apr; 19(2):E31-5. PubMed ID: 25840395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases.
    McGann S; Horton ER
    Ann Pharmacother; 2015 Apr; 49(4):469-76. PubMed ID: 25573268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radium Ra 223 dichloride in castration-resistant prostate cancer.
    Joung JY; Ha YS; Kim IY
    Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer.
    Matsubara N; Nagamori S; Wakumoto Y; Uemura H; Kimura G; Yokomizo A; Kikukawa H; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Tsutsui H; Uemura H
    Int J Clin Oncol; 2018 Feb; 23(1):173-180. PubMed ID: 28770408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
    Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
    Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
    Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radium-223 in the treatment of osteoblastic metastases: a critical clinical review.
    Humm JL; Sartor O; Parker C; Bruland OS; Macklis R
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):898-906. PubMed ID: 25832684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
    Winter BM; von Rundstedt FC; Grimm MO
    Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases].
    Heinzer H; König F; Klutmann S
    Urologe A; 2014 Apr; 53(4):519-23. PubMed ID: 24604017
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Dizdarevic S; Jessop M; Begley P; Main S; Robinson A
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2264-2273. PubMed ID: 29998419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective.
    Shore ND
    Urology; 2015 Apr; 85(4):717-24. PubMed ID: 25681834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
    Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
    Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer.
    Du Y; Carrio I; De Vincentis G; Fanti S; Ilhan H; Mommsen C; Nitzsche E; Sundram F; Vogel W; Oyen W; Lewington V
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1671-1678. PubMed ID: 28631036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223.
    Rodriguez-Vida A; Torregrosa MD; Pinto Á; Climent MÁ; Olmos D; Carles J
    Clin Transl Oncol; 2018 Jun; 20(6):679-686. PubMed ID: 29098556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
    Jacene H; Gomella L; Yu EY; Rohren EM
    Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical guide to the use of radium 223 dichloride.
    Den RB; Doyle LA; Knudsen KE
    Can J Urol; 2014 Apr; 21(2 Supp 1):70-6. PubMed ID: 24775727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When to initiate treatment with radium-223 in patients with metastatic castration-resistant prostate cancer.
    Shore ND
    Clin Adv Hematol Oncol; 2016 Jan; 14(1):26-9. PubMed ID: 27057663
    [No Abstract]   [Full Text] [Related]  

  • 19. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
    Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
    Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).
    Yoshida S; Takahara T; Arita Y; Ito M; Hayakawa S; Oguchi T; Komai Y; Numao N; Yuasa T; Inoue M; Ushijima H; Kudo S; Shimano Y; Nakamura Y; Uchida Y; Uehara S; Tanaka H; Yaegashi H; Izumi K; Yokoyama M; Matsuoka Y; Yoshioka Y; Konishi K; Nakanishi K; Nagahara A; Hirakawa A; Koike R; Koga F; Nishimura K; Mizokami A; Yonese J; Kageyama Y; Yoshimura R; Fujii Y
    BMC Urol; 2023 Mar; 23(1):33. PubMed ID: 36879257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.